| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Inventory, net | - | 467 | ||
| Cash and cash equivalents | 2,309 | 5,344 | ||
| Accounts receivable, net | 368 | - | ||
| Prepaid expenses and other current assets | 221 | 304 | ||
| Current assets, discontinued operations | 0 | 0 | ||
| Total current assets | 2,898 | 6,115 | ||
| Operating lease right-of-use assets | 189 | 306 | ||
| Property and equipment, net | 6 | 11 | ||
| Other assets | 394 | 479 | ||
| Other assets, discontinued operations | 0 | 0 | ||
| Total assets | 3,487 | 6,911 | ||
| Accounts payable | 76 | 604 | ||
| Accrued liabilities | 807 | 1,020 | ||
| Bridge loan | 0 | 0 | ||
| Unsecured convertible notes, net of discounts | 149 | 111 | ||
| Operating lease liabilities | 416 | 409 | ||
| Current liabilities, discontinued operations | 0 | 0 | ||
| Total current liabilities | 1,448 | 2,144 | ||
| Operating lease liabilities-non-current | 405 | 522 | ||
| Total liabilities | 1,853 | 2,666 | ||
| Series f preferred stock 1,987 and 0 shares issued and outstanding at september 30, 2025 and december 31, 2024, respectively-Series FPreferred Stock | 525 | - | ||
| Preferred stock, value, issued-Series BPreferred Stock | 6 | 6 | ||
| Preferred stock, value, issued-Series DPreferred Stock | 3,786 | - | ||
| Common stock, 0.01 par value 150,000 shares authorized, 6,011 and 4,885 shares issued and outstanding at september 30, 2025 and december 31, 2024, respectively | 60 | 58 | ||
| Additional paid-in capital | 181,074 | 181,890 | ||
| Accumulated deficit | -183,817 | -177,709 | ||
| Total stockholders equity (deficit) | 1,109 | 4,245 | ||
| Total liabilities, mezzanine equity and stockholders equity (deficit) | 3,487 | 6,911 | ||
NovaBay Pharmaceuticals, Inc. (NBY)
NovaBay Pharmaceuticals, Inc. (NBY)